FDA places hold on Ebvallo (tabelecleucel) for treatment of Epstein-Barr virus and ATA 3219 for the treatment of non-Hodgkin’s lymphoma – Atara Biotherapeutics
Atara Biotherapeutics, Inc. a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases,… read more.
